| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 114 companies in the Pharmaceuticals industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Feb 15, 2019 | AMRN Amarin Corp Plc\uk | Kalb Michael Wayne | SVP And CFO | Sell | 25,000 | $17.58 | $439,525.00 | -54.9% | |
| Feb 15, 2019 | COLL Collegium Pharmaceutical, Inc | Heffernan Michael Thomas | Director | Sell | 25,000 | $14.81 | $370,223.80 | -4.7% | |
| Feb 15, 2019 | AMPH Amphastar Pharmaceuticals, Inc. | Peters William J52 | CFO, SVP &Treasurer | Sell | 10,016 | $24.37 | $244,089.92 | -11.7% | |
| Feb 14, 2019 | TEVA Teva Pharmaceutical Industries Ltd | Fridriksdottir Hafrun47 | Executive VP, Global R&D | Sell | 1,841 | $17.67 | $32,528.63 | -10.7% | |
| Feb 14, 2019 | AMPH Amphastar Pharmaceuticals, Inc. | Shandell Jason B. | President And General Counsel | Sell | 7,519 | $23.99 | $180,380.81 | -4.3% | |
| Feb 14, 2019 | TEVA Teva Pharmaceutical Industries Ltd | Stark David Matthew53 | Exec. VP Chief Legal Officer | Sell | 3,926 | $17.74 | $69,647.24 | -56.9% | |
| Feb 14, 2019 | TEVA Teva Pharmaceutical Industries Ltd | De Notaristefani Carlo | Executive VP Global Operations | Sell | 3,192 | $17.67 | $56,399.45 | -14.9% | |
| Feb 14, 2019 | MRK Merck & Co., Inc. | Karachun Rita A | Sr. VP Fince-global Controller | Sell | 64,662 | $78.96 | $5,105,950.77 | -80.0% | |
| Feb 14, 2019 | AMPH Amphastar Pharmaceuticals, Inc. | Liawatidewi Yakob47 | SVP Corp Admin Center | Sell | 8,868 | $23.86 | $211,632.00 | -11.0% | |
| Feb 13, 2019 | SNY Sanofi | Sanofi | 10% Owner | Sell | 4,168,899 | $37.66 | $157,000,736.34 | -100% | |
| Feb 13, 2019 | BUDZ Weed, Inc. | Breen Nicole M | Secretary And Treasurer | Sell | 4,000 | $1.46 | $5,840.00 | - | |
| Feb 13, 2019 | MRK Merck & Co., Inc. | Weeks Wendell P62 | Director | Sell | 5,000 | $78.71 | $393,547.50 | -98.0% | |
| Feb 13, 2019 | TEVA Teva Pharmaceutical Industries Ltd | De Notaristefani Carlo | Executive VP Global Operations | Sell | 5,041 | $17.88 | $90,107.88 | -29.4% | |
| Feb 12, 2019 | BUDZ Weed, Inc. | Breen Nicole M | Secretary And Treasurer | Sell | 3,700 | $1.47 | $5,423.10 | - | |
| Feb 12, 2019 | MRK Merck & Co., Inc. | Chattopadhyay Sanat | Exe V-p &Pres. Mmd | Sell | 73,727 | $78.62 | $5,796,306.15 | -58.9% | |
| Feb 8, 2019 | MRK Merck & Co., Inc. | Brun Leslie A | Director | Sell | 3,052 | $77.22 | $235,680.63 | -61.0% | |
| Feb 8, 2019 | LFCR Lifecore Biomedical, Inc. \de\ | Obus Nelson | Director | Buy | 12,900 | $12.12 | $156,340.00 | +0.2% | |
| Feb 7, 2019 | BUDZ Weed, Inc. | Breen Nicole M | Secretary And Treasurer | Sell | 22,500 | $1.54 | $34,550.00 | - | |
| Feb 6, 2019 | NBIX Neurocrine Biosciences Inc | Lippoldt Darin60 | Chief Legal Officer | Sell | 791 | $83.52 | $66,063.37 | -3.9% | |
| Feb 6, 2019 | NBIX Neurocrine Biosciences Inc | Benevich Eric62 | Chief Commercial Officer | Sell | 920 | $83.57 | $76,883.02 | -4.2% | |
| Feb 6, 2019 | LNTH Lantheus Holdings, Inc. | Orlandi Cesare | Chief Medical Officer | Sell | 4,057 | $18.06 | $73,269.42 | -5.2% | |
| Feb 6, 2019 | NBIX Neurocrine Biosciences Inc | Gano Kyle54 | Chief Business Development Off | Sell | 762 | $83.56 | $63,672.64 | -0.9% | |
| Feb 6, 2019 | NBIX Neurocrine Biosciences Inc | Lloyd-Smith Malcolm49 | Chief Regulatory Officer | Sell | 920 | $83.58 | $76,893.78 | -4.6% | |
| Feb 6, 2019 | LFCR Lifecore Biomedical, Inc. \de\ | Obus Nelson | Director | Buy | 20,000 | $12.38 | $247,600.00 | +0.7% | |
| Feb 6, 2019 | NBIX Neurocrine Biosciences Inc | Grigoriadis Dimitri E. | Chief Research Officer | Sell | 531 | $84.03 | $44,621.58 | -0.4% |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.